TY - JOUR
T1 - Predicting the clinical efficacy of house dust mite immunotherapy in bronchial asthmatics by multiple quantification analysis type II
AU - Soda, R.
AU - Okada, C.
AU - Takahashi, K.
AU - Katagi, S.
AU - Kanehiro, A.
AU - Kimura, G.
AU - Okamoto, S.
AU - Tada, S.
AU - Kimura, I.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1993
Y1 - 1993
N2 - To predict the clinical efficacy of house dust mite immunotherapy (IT) for bronchial asthma, clinical factors before IT were analyzed in relation to clinical efficacy. The factors analyzed were severity, skin test threshold, age at which IT was started, duration of asthma, onset of asthma, FEV 1.0%, serum IgE levels before IT, the presence of allergens other than HD, family history of atopic disease, complications with other allergic diseases, sex, seasonality of attacks and the maintenance dose. The clinical efficacy ranging from good response to no benefit was well discriminated by this analysis. The rate of discrimination was about 90%, indicating clinical usefulness of the method. In this study, skin test threshold seemed to be the most important factor, followed by FEV 1.0%. While severity and age have been reported to be important, those who show good FEV 1.0% and low skin test threshold, regardless of their severity or age, may be good candidates for IT.
AB - To predict the clinical efficacy of house dust mite immunotherapy (IT) for bronchial asthma, clinical factors before IT were analyzed in relation to clinical efficacy. The factors analyzed were severity, skin test threshold, age at which IT was started, duration of asthma, onset of asthma, FEV 1.0%, serum IgE levels before IT, the presence of allergens other than HD, family history of atopic disease, complications with other allergic diseases, sex, seasonality of attacks and the maintenance dose. The clinical efficacy ranging from good response to no benefit was well discriminated by this analysis. The rate of discrimination was about 90%, indicating clinical usefulness of the method. In this study, skin test threshold seemed to be the most important factor, followed by FEV 1.0%. While severity and age have been reported to be important, those who show good FEV 1.0% and low skin test threshold, regardless of their severity or age, may be good candidates for IT.
KW - bronchial asthma
KW - house dust mite
KW - immunotherapy
KW - multi-factorial analysis
KW - prospective factor
UR - http://www.scopus.com/inward/record.url?scp=0027772085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027772085&partnerID=8YFLogxK
M3 - Article
C2 - 8110037
AN - SCOPUS:0027772085
VL - 42
SP - 1771
EP - 1775
JO - Japanese Journal of Allergology
JF - Japanese Journal of Allergology
SN - 0021-4884
IS - 12
ER -